This is an open-label phase I study of TRK-950 in patients with histologically and cytologically confirmed, metastatic or unresectable solid tumors who are refractory or intolerant to standard therapy or for whom no standard therapy exists. The objectives of this study are to determine the safety, tolerability, pharmacokinetic (PK) profile and the incidence of the development of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against TRK-950.
The main purpose of this study is to determine the safety and tolerability of TRK-950 in patients with advanced solid tumors.